The Tailored EDVTM trial: A phase I feasibility study evaluating EGFR-targeted EDVTM nanocells as a therapy platform in patients with refractory advanced solid tumours

被引：1
|
作者：
Clarke, S. [1 ]
Sidhu, S. [2 ]
Pavlakis, N. [1 ]
Brahmbhatt, H. [3 ]
Macdiarmid, J. [3 ]
机构：
[1] Univ Sydney, Northern Canc Inst, Sydney, NSW, Australia
[2] Univ Sydney, Endocrine Surg Unit, Sydney, NSW, Australia
[3] EnGeneIC, Biotechnol, Sydney, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.55
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
412TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEGinterferon alpha-2b in patients with refractory or advanced solid tumours
    Coker, Shodeinde A.
    Dandamudi, Uday B.
    Beelen, Andrew P.
    Crosby, Nancy A.
    Fisher, Jan L.
    Obrocea, Michael
    Ernstoff, Marc S.
    Lewis, Lionel D.
    JOURNAL OF CHEMOTHERAPY, 2013, 25 (06) : 362 - 368
  • [22] Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
    Kaufman, Jonathan L.
    Gasparetto, Cristina
    Schjesvold, Fredrik H.
    Moreau, Philippe
    Touzeau, Cyrille
    Facon, Thierry
    Boise, Lawrence H.
    Alzate, Stefanie
    Macartney, Tammy
    Pesko, John
    Salem, Ahmed Hamed
    Ross, Jeremy A.
    Hong, Wan-Jen
    Maciag, Paulo C.
    Pauff, James M.
    Kumar, Shaji K.
    BLOOD, 2019, 134
  • [23] Strata A and B of the phase I INSIGHT platform trial evaluating feasibility and safety of intratumoral and intraperitoneal eftilagimod alpha (soluble LAG-3 protein) in advanced stage solid tumors entities
    Goetze, T. O.
    Mueller, D. W.
    Rafiyan, M. -R.
    Kiselicki, D.
    Habibzade, T.
    Brignone, C.
    Schaaf, M.
    Eickhoff, R.
    Jaeger, E.
    Al-Batran, S. -E.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 232 - 232
  • [24] Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
    D Mahalingam
    G Wilding
    S Denmeade
    J Sarantopoulas
    D Cosgrove
    J Cetnar
    N Azad
    J Bruce
    M Kurman
    V E Allgood
    M Carducci
    British Journal of Cancer, 2016, 114 : 986 - 994
  • [25] Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
    Mahalingam, D.
    Wilding, G.
    Denmeade, S.
    Sarantopoulas, J.
    Cosgrove, D.
    Cetnar, J.
    Azad, N.
    Bruce, J.
    Kurman, M.
    Allgood, V. E.
    Carducci, M.
    BRITISH JOURNAL OF CANCER, 2016, 114 (09) : 986 - 994
  • [26] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours.
    Shaw, H.
    Plummer, R.
    Vidal, L.
    Perrett, R.
    Pilkington, M.
    Temple, G.
    Fong, P.
    Amelsberg, A.
    Calvert, H.
    De Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 127S - 127S
  • [27] Safety and dose-escalation study of a targeted oncolytic adenovirus, suratadenoturev (OBP-301), in patients with refractory advanced liver cancer: Phase I clinical trial
    Heo, Jeong
    Liang, Ja-Der
    Kim, Chang Won
    Woo, Hyun Young
    Shih, I-Lun
    Su, Tung-Hung
    Lin, Zhong-Zhe
    Chang, Stanley
    Urata, Yasuo
    Chen, Pei-Jer
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [28] Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.
    Goetze, Thorsten Oliver
    Mueller, Daniel Wilhelm
    Rafiyan, Mohammad-Reza
    Kiselicki, Dragan
    Habibzade, Timursah
    Schaaf, Marina
    Eickhoff, Regina
    Jaeger, Elke
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
    Hollebecque, A.
    de Bono, J. S.
    Salvagni, S.
    Plummer, R.
    Niccoli, P.
    Capdevila, J.
    Curigliano, G.
    Moreno, V.
    de Braud, F.
    Lopez-Brea, M.
    Martin-Romano, P.
    Baudin, E.
    Arias, M.
    de Alvaro, J.
    Parra-Palau, J.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S464 - S464
  • [30] Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours
    Haruo Iguchi
    Tomohiro Nishina
    Naoyuki Nogami
    Toshiyuki Kozuki
    Yumiko Yamagiwa
    Katsuro Yagawa
    Investigational New Drugs, 2015, 33 : 194 - 200
12345